RT Journal Article
SR Electronic
T1 Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1505
OP 1513
DO 10.21873/invivo.13950
VO 39
IS 3
A1 YAMAGUCHI, TOSHIFUMI
A1 YOSHIDA, MOTOKI
A1 TAIRA, KOICHI
A1 TOKUNAGA, SHINYA
A1 KATO, TAKESHI
A1 NAKAMURA, MASATO
A1 SUGIMOTO, NAOTOSHI
A1 FUMITA, SOICHI
A1 YASUI, MASAYOSHI
A1 MIYAKE, YASUHIRO
A1 KAWAKAMI, HISATO
A1 KUROKAWA, YUKINORI
A1 SHIMOKAWA, TOSHIO
A1 SATOH, TAROH
YR 2025
UL http://iv.iiarjournals.org/content/39/3/1505.abstract
AB Background/Aim: The combination of capecitabine and bevacizumab is a standard first-line chemotherapy regimen for vulnerable patients with unresectable colorectal cancer. However, the safety and efficacy of this regimen in Japanese patients have not been sufficiently investigated.Patients and Methods: This phase II study included patients aged ≥76 years or those aged 65-75 years who were unsuitable for intensive chemotherapy. Capecitabine at 2000 mg/m2/day (days 1-14) plus bevacizumab at 7.5 mg/kg (day 1) were administered every 3 weeks. The primary endpoint was progression-free survival. Secondary endpoints included overall survival, response rate, disease control rate, and toxicities.Results: Thirty-six patients were enrolled between July 2011 and July 2014, of whom 33 were included in the analysis. The median patient age was 78 years (range=67-86 years). A total of 28 patients had a performance status of 0 or 1, and five of 2. The median progression-free and overall survival were 10.3 (95% confidence interval=9.2-15.4) and 27.9 (95% confidence interval=24.2-50.1) months, respectively. The response and disease control rates were 30.3% and 91.0%, respectively. The major grade 3 or 4 toxicities were hypertension (n=12, 36%) and hand-foot syndrome (n=4, 12%). One patient experienced a grade 4 gastrointestinal perforation.Conclusion: The combination of capecitabine and bevacizumab demonstrated favorable efficacy and tolerability in Japanese patients with metastatic colorectal cancer who were unsuitable for intensive chemotherapy.